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Protracted dormancy of pre-leukemic stem cells
AM Ford1, MB Mansur1,2, CL Furness1, FW van Delft3, J Okamura4, T Suzuki5, H Kobayashi5, Y Kaneko5 and M Greaves1
Cancer stem cells can escape therapeutic killing by adopting a quiescent or dormant state. The reversibility of this condition
provides the potential for later recurrence or relapse, potentially many years later. We describe the genomics of a rare case of
childhood BCR-ABL1-positive, B-cell precursor acute lymphoblastic leukemia that relapsed, with an acute myeloblastic leukemia
immunophenotype, 22 years after the initial diagnosis, sustained remission and presumed cure. The primary and relapsed
leukemias shared the identical BCR-ABL1 fusion genomic sequence and two identical immunoglobulin gene rearrangements,
indicating that the relapse was a derivative of the founding clone. All other mutational changes (single-nucleotide variant and copy
number alterations) were distinct in diagnostic or relapse samples. These data provide unambiguous evidence that leukemia-
propagating cells, most probably pre-leukemic stem cells, can remain covert and silent but potentially reactivatable for more than
two decades.
Leukemia (2015) 29, 2202–2207; doi:10.1038/leu.2015.132
INTRODUCTION
Recurrence or relapse of cancer many years1–3 or occasionally
decades4 after an initial diagnosis has been frequently recorded.
These observations raise difficult issues related to presumptions of
cure, risk assessment and monitoring of residual disease.
A plausible mechanism for persistent, covert cancer cells during
and after treatment is provided by the observation that some
cancer stem cells can adapt a reversible quiescent or dormant
state in which they are relatively resistant to radiation and
chemotherapy.5–8 However, the assumption is usually made
that late recurring cancer is a derivative of the original clone at
diagnosis, evidence for which is very limited, with the exception
of some acute leukemias where physiological rearrangement
of immunoglobulin genes (IGH/IGK) provide clone-specific
markers.9–11
MATERIALS AND METHODS
Targeted capture libraries, cloning and sequencing of gene fusions
A cell line, MR-87, was established from the original leukemic cells of the
4-year-old patient and it showed the same immunophenotype and
karyotype of the diagnostic leukemic cells. These cells were also shown to
express the p190 BCR-ABL1 protein.12 Illumina paired-end libraries
(Illumina, San Diego, CA, USA) covering the entire genomic regions of
the BCR, ABL1 and IKZF1 genes were prepared from the MR87 cell line DNA
(diagnosis) using the Agilent SureSelectXT 2 Custom (1–499 kb) DNA bait
library (Agilent Technologies, Santa Clara, CA, USA). The custom libraries
were sequenced on a HiSeq2500 (Illumina) to a coverage depth of 99 × .
Casava software (v1.8, Illumina) was used to make base calls and
demultiplex the sequencing data and the genomic fusion breakpoints of
BCR-ABL1 and IKZF1 were roughly determined using Burrows–Wheeler
Aligner and Breakdancer software (The Genome Institute, St Louis, MO,
USA). The BCR-ABL1 breakpoint fusion was predicted based on the location
of read pairs that mapped to the fusion partners and the average fragment
size of the capture library (320 bp). Using GRCh37.p13, the predicted
breakpoint region in BCR was at chr22:23533568–23533950 (intron 1) and
the breakpoint region in ABL1 was expected at chr9:133608500–
133608811 (intron 1). A large deletion in IKZF1 (~50 kb) was observed
between regions chr7:50412887–50463541. PCR primers were then
designed to span the putative breakpoints using Primer3 plus
(www.primer3plus.com/). Primers used for cloning the BCR-ABL1 fusion
were: 5′-GTCAAAGCATTTTCCCCTGC-3′ and 5′-TCTTGATACTGGGTTGGCTGC
-3′, and for the IKZF1 deletion were: 5′-GTCCTGGGTTTAAGCTTCAGTTCTC
TGCCT-3′ and 5′-GGGTTGATAAGGAGGGTTTTGTGTCCCAGT-3′. Patient-
specific gene fusions were amplified using AccuPrime Taq DNA Polymerase
High Fidelity (Life Technologies, Carlsbad, CA, USA) and PCR products
sequenced using BigDye Terminator v1.1 and an ABI-3730xl Genetic
Analyzer (Applied Biosystems, Warrington, UK). Sequences were aligned by
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Screening for IG and TCR gene rearrangements
DNA was extracted from diagnostic (MR87) and relapse cells (peripheral
blood and bone marrow). PCR amplification of immunoglobulin (IG) heavy-
chain variable–diversity–joining (IGH V(D)J; complete and incomplete), IGκ
variable–joining (IGK-VJ), IGK Vκ-deleting element (Kde), intron recombina-
tion signal sequence–Kde, IGλ (IGL), T-cell receptor-β (TCRB), TCRγ (TCRG)
and TCRδ gene rearrangements were performed using primers and
conditions recommended by the BIOMED-2 Consortium.13 The 6-carboxy-
fluorescein labelled products were analysed using an ABI 3500 Genetic
Analyzer (Applied Biosystems), clonality was assessed by GeneScan
software (Applied Biosystems) and the results were interpreted in
accordance with the EuroClonality/BIOMED-2 guidelines.14 PCR products
were cloned into pCR2.1 (Life Technologies), sequenced and analysed as
above. Junction analyses were performed using IgBLAST (www.ncbi.nlm.
nih.gov/igblast/) and the ImMunoGeneTics database (www.imgt.org/).
Genome-wide copy number analysis
Single-nucleotide polymorphism array analysis was carried out using
Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, CA, USA), according to
the manufacturer’s instructions, on DNA extracted using standard methods
from the diagnostic cell line (MR87) and from relapse bone marrow.
Genotyping and generation of quality control data were performed in
Genotyping Console v4.1.4 software (Affymetrix). The sample files were
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scrutinised for copy number alteration (CNAs) by visual inspection and by
using the Partek Genomics Suite 6.6 software (Partek, St Louis, MO, USA).
Copy number was determined by normalisation to Partek-distributed
baseline files, which comprise 270 Hapmap files, using a genomic
segmentation algorithm.
Whole exome sequencing
Exome capture was performed using the Agilent SureSelect Human All
Exon V5 kit as per the manufacturer’s instructions (Agilent) and sequenced
by Illumina paired-end sequencing (protocol v1.2). Briefly, DNA was
sheared by fragmentation (Covaris, Woburn, MA, USA), purified using
Agencourt AMPure XP beads (Beckman Coulter, Pasadena, CA, USA) and
the resulting fragments analysed on an Agilent 2100 Bioanalyzer. Fragment
ends were repaired and adaptors ligated to the fragments, and the library
was purified using beads. After amplification and hybridisation with
biotinylated RNA baits, bound genomic DNA was purified with
streptavidin-coated magnetic Dynabeads (Life Technologies) and
re-amplified to include barcoding tags before finally pooling for
sequencing on an Illumina HiSeq 2000.
Exome analysis was completed in Oxford Gene Technology’s (Begbroke, UK)
exome pipeline. Briefly, reads were aligned to the human genome
reference sequence GRCh37 using Burrows–Wheeler Aligner 0.6.2.15 Local
realignment was performed around indels with the Genome Analysis
Toolkit (GATK v1.6) IndelRealigner.16 Optical and PCR duplicates were
marked in BAM files using Picard 1.107 (http://picard.sourceforge.net).
Original HiSeq base quality scores were recalibrated using GATK
TableRecalibration and per-sample variants called with GATK UnifiedGen-
otyper (Broad Institute, Cambridge, MA, USA). Indels and single-nucleotide
variants (SNVs) were hard filtered according to the Broad Institute
best-practice guidelines, to eliminate false-positive cells.
Copy number variants, somatic SNV and somatic indels were identified
between presentation and relapse samples using VarScan2.17 Variant
annotation was performed with a modified version of Ensembl Variant
Effect Predictor.18
RESULTS
Clinical and haematological features of case
A brief case report of the patient was already published19 and is
summarised as follows. A 4-year-old boy was diagnosed as having
precursor B-cell acute lymphoblastic leukemia (ALL) but with a
mixed lympho-myeloid phenotype: positive for myeloperoxidase,
CD13+, CD10+ and CD19+. Cytogenetics on leukemic cells showed
46,XY,9p− ,t(9q+;22q− ), indicating Ph+ pre-B-ALL. Reverse
transcriptase-PCR confirmed the presence of the minor breakpoint
(p190) BCR-ABL1 fusion.
The patient was treated with chemotherapy and achieved
complete remission. Eight weeks after the diagnosis, he developed
a central nervous system relapse, which was successfully treated
with cranial irradiation and intrathecal drug administration. Three
months after the diagnosis, he received a bone marrow transplant
(BMT) from his human leukocyte antigen-identical (non-twin)
brother when in the second complete remission. BMT transplanta-
tion was successful and no major complications were observed.
At the age of 25 years (20 years after BMT transplantation), the
patient presented with general fatigue. His white blood cell count
was 16.7 × 109/l with 7% blasts and his bone marrow aspirates
showed leukemic cells with a myeloid immunophenotype positive
for CD13 and CD33, and negative for CD10 and CD19. The
leukemic cell karyotype was 46,XY,t(9;22)(q34;q11) × 2 plus other
complex abnormalities. He was tentatively diagnosed as having a
relapse of the initial Ph+ pre-B-ALL and received intensive
chemotherapy resulting in complete remission. He underwent
the second BMT transplant from a human leukocyte antigen-
identical unrelated donor but had bone marrow relapse 35 weeks
after the second BMT transplant and subsequently died of the
disease.
Diagnostic and late relapse clones share an identical BCR-ABL1
fusion sequence
The putative breakpoint regions of the BCR and ABL1 genes were
identified by targeted whole-genome sequencing of DNA isolated
from the cell line (MR87) derived from patient cells at diagnosis.
PCR primers were designed 5′ to the putative breakpoint in
BCR and 3′ to that in ABL1, and the patient-specific BCR-ABL1 gene
fusion was amplified, cloned and sequenced. The breakpoint
detected in the BCR gene occurred within intron 1 at GRCh37.p13
position ch22:23533768 and within intron 1 of the ABL1 gene at
position ch9:133608599 (Figure 1). The breaks in both BCR and
ABL1 are therefore outside the recognised cluster regions
described for Ph+ leukemia.20 The same set of PCR primers were
next used to interrogate DNA from the peripheral blood and bone
marrow at relapse and an identical sized fusion product was
obtained. Cloning and sequencing of the relapse fusion products
proved the BCR-ABL1 fusion sequence to be identical to that
present at diagnosis (Figure 1a).
Genome-wide copy number analysis
SNP 6.0 analysis on DNA isolated from the diagnostic cell line
showed the following recurrent leukemia CNA: deletion of MTAP,
CDKN2A/B, PAX5, 6q14.1–6q16.1 and IKZF1. In addition, amplifica-
tion of MDM2 was noted. Relapse material was discordant for the
diagnostic CNA drivers (Table 1); however, copy number loss of 9p
was demonstrated (including loss of the same genes deleted at
diagnosis: CDKN2A/B, MTAP and PAX5) but results clearly demon-
strated that this 9p deletion was a re-iterative event with distinct
breakpoints to the diagnostic sample (Supplementary Tables S1
and S2, and Supplementary Figures S1A–F). Potential drivers
newly acquired in the relapse material also included deletion of
the majority of chromosome 21q, gain of chromosome 20 and
deletion of 8p (Supplementary Table S2).
Given that deletions in the tumour suppressor gene IKZF1 are
considered a driving force of leukemogenesis, we used targeted
sequencing of diagnostic DNA to design PCR primers that
spanned the putative boundaries of the 50 kb IKZF1 intra-gene
deletion. Subsequent PCR produced an ~ 4 kb amplification
product that was further cloned and sequenced (Figure 1b). The
5′-breakpoint was determined at GRCh37.p13 position 7:50412893
and the 3′-breakpoint at position 7:50463650, with loss of 50
757 bp of DNA and the random insertion of 3 nucleotides
(Figure 1b). Using the same primer set, we could not detect a
deletion in the IKZF1 gene by conventional PCR or sensitive
quantitative PCR in the peripheral blood or bone marrow at
relapse (Figure 1b and Supplementary Figures S2 and S5). These
data indicate that some genes (IKZF1 and CDKN2A) were subject to
reiterated CNA in diagnosis and relapse but no CNA was preserved
from diagnosis to relapse.
Clonality of immunoglobulin gene rearrangements at diagnosis
and relapse
Screening for clonal IG and TCR gene rearrangements to assess
clonality was performed on both the diagnostic and relapse DNA
using multiplex PCR reactions and ABI GeneScan profiling. Clonal
rearrangements were identified in both IGH VDJ (FR1 and 2) and
IGL VJK reactions (Figure 2 and Supplementary Figure S3) with
weaker clonal rearrangements observed in TCRBB/C and in TRG1
(data not shown). A V(N)JK light-chain rearrangement was shown
to be identical between diagnosis and relapse (Figure 2), and the
two major IGH V(N)D(N)J peaks identified at 294 and 335 bp at
diagnosis were similarly shown to have identical sequences to the
respective minor peaks observed at relapse (Supplementary
Figure S3). However, the two major peaks identified in relapse
at 330 and 341 bp were not detected in diagnostic material by
conventional or quantitative PCR (Supplementary Figure S4).
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One interpretation of these data is that the ‘founder’ IGH
rearrangement present in the diagnostic samples underwent further
rearrangement in relapse. Taken together, these data further
suggest that the diagnostic and relapse clones may have arisen
from a pre-leukemic progenitor cell already partially committed to
the B-cell lineage. However, the myeloid or acute myeloblastic
leukemia immunophenotype seen in relapse indicates that the
leukemia was essentially ‘mixed lympho-myeloid’ and may have
Figure 1. Diagnostic and late relapse clones share an identical BCR-ABL1 fusion sequence with a discordant intra-gene deletion of IKZF1. (a)
Upper panel: PCR primers that span the BCR-ABL1 breakpoint identified in diagnostic material (MR87, CL) were used to interrogate DNA
isolated at relapse (bone marrow (BM) and peripheral blood (PB)). An identical product is seen in all patient samples but not in leukemia
controls. Lower panel: DNA sequence of the BCR-ABL1 fusion and comparison with wild-type BCR and ABL1 gene sequences (GRCh37.p13). The
DNA sequence was identical in both diagnostic and relapse samples. (b) Upper panel: DNA fusion sequence (GRCh37.p13) of the IKZF1
deletion at diagnosis reveals a 50-kb deletion between introns 2 and 7. Lower panel: the deletion/fusion product present at diagnosis (MR87
and CL) is not observed at relapse (BM and PB) or in DNA from leukemia controls.
Table 1. Summary of ‘driver’ CNAs present at diagnosis versus relapse detected by SNP analysis
Chr Start End Cytoband CNA loss/gain Diagnosis Relapse Genes (max three listed)
1 chr6 78095353 93349377 6q14.1–6q16.1 Loss Present Absent IRAK1BP1, PHIP, SYNCRIP
2 chr7 50389071 50477011 7p12.2 Loss Present Absent IKZF1
3 chr9 16523946 21901150 9p22.3–9p21.3 Loss Present Absent MLLT3, MTAP, FOCAD
4 chr9 21901150 22347406 9p21.3 Homozygous Loss Present Absent CDKN2A, CDKN2B
5 chr9 36412035 38493465 9p13.2–9p13.1 Loss Present Absent MELK, PAX5, FRMPD1
6 chr12 68970862 69406845 12q15 Gain Present Absent RAP1B, NUP107, MDM2
7 chr 7 50389060 50486601 7p12.2 Loss Absent Present IKZF1
8 chr8 31254 43078119 8p23.3–8p11.21 Loss Absent Present ZNF596, FBXO25, DLGAP2
9 chr9 6988784 21926959 9p24.1–9p21.3 Loss Absent Present MPDZ, MLLT3, MTAP
10 chr9 21926959 22200408 9p21.3 Heterozygous Loss Absent Present CDKN2A, CDKN2B
11 chr9 22200408 132070825 9p21.3–9q34.11 Loss Absent Present MOB3B, LINGO2, PAX5
12 chr20 61305 62956154 20p13–20q13.33 Gain Absent Present DEFB125, DEFB126, TOP1
13 chr21 15939316 48096958 21q11.2–21q22.3 Loss Absent Present CHODL,CXADR,NCAM2
Abbreviations: CNA, copy number alteration; SNP, single-nucleotide polymorphism. Based on NCBI37/hg19 assembly.
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arisen in a cell with some myeloid differentiation capacity despite
the clonal IGH rearrangements present in the bulk cell progeny.
Whole exome sequencing analysis
We performed whole exome sequencing on patient DNAs isolated
at diagnosis, remission (germline) and relapse. All possible cross-
comparisons between these three time points were assessed in
the data analyses. In terms of somatic alterations, at diagnosis
we identified, before filtering, a total of 2189 SNVs and 648
insertions and/or deletions. At relapse we identified 7320 SNVs
and 1567 indels.
In further analyses, we highlighted relevant functional altera-
tions. In the diagnostic sample, after filtering the data by read
depth (between 30–170 × ), coding areas only and SNVs predicted
to alter protein structure and deleterious/possibly damaging at
the protein level (Ensembl Variant Effect Predictor), we detected
92 somatic SNVs and 59 indels. We selected those genes with
functions known to be associated with cancer of which there were
12—SNVs: NOTCH2, PIK3CG, IL2RB, BAI3, FREM2 and RERE; indels:
UTRN, CDHR3, NCOA5, CABYR, HOTAIR and FOLH1 (Table 2). In the
relapse sample after a similar filtration, we identified 156 SNVs and
46 indels, and identified 10 potential ‘driver’ genes—SNVs: THOC6,
VANGL2, THBS1, STAT2 and ACY1; indels: NBEAL1, SMG7, TRIM29,
FANCG and FAM186A (Table 2). All 22 genes have previously been
shown to have a relevant role in tumourigenesis or have potential
to be a ‘driver’ of leukemogenesis. We confirmed selected
heterozygous point mutations or indels by Sanger sequencing,
that is, NOTCH2, HOTAIR, STAT2 and FANCG (data not shown).
None were shared between the diagnostic and relapse samples,
and were absent in remission (control, constitutive DNA).
DISCUSSION
The identity of shared and clone-specific genotypic sequences in
this patient’s diagnostic and very late relapse leukemia cell
population provides unambiguous evidence that the relapse
Figure 2. Clonality of immunoglobulin light chain gene rearrangements at diagnosis and relapse. Upper panel: PCR amplifications of IGλ (IGL V
(N)J) rearrangements at diagnosis and relapse were assessed by GeneScan software. Lower panel: DNA sequence analysis of the major V(N)J
rearrangement identified at diagnosis shows an identical sequence to that observed at relapse. N region insertion is shown in bold italics.
Table 2. Principal mutations detected by whole exome sequencing of
the patient DNA at diagnosis and relapse
Genes Diagnosis Relapse 
SNV1 NOTCH2 
SNV2 PIK3CG
SNV3 IL2RB 
SNV4 BAI3 
SNV5 FREM2
SNV6 RERE
Ind1 UTRN 
Ind2 CDHR3 
Ind3 NCOA5 
Ind4 CABYR 
Ind5 HOTAIR 
Ind6 FOLH1 
SNV7 THOC6 
SNV8 VANGL2 
SNV9 THBS1 
SNV10 STAT2
SNV11 ACY1 
Ind7 NBEAL1 
Ind8 SMG7
Ind9 TRIM29 
Ind10 FANCG 
Ind11 FAM186A
Abbreviations: SNV, single-nucleotide variant; WT, wild type.
Somatic SNV. Somatic Inddel. WT. List of the relevant genes
affected by somatic mutations (SNVs and indels) at diagnosis and relapse.
The remission (germline) sample was also evaluated and did not harbour
any of these mutations, thus confirming their somatic/clonal origin. The
colours differentiate SNVs (light grey) from indels (dark grey).
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derived, after 22 years, from descendent progeny of the original
founder clone (Figure 3). Late relapses derived from the founder
diagnostic clones in ALL have been described before,9,10 but this is
the longest dormancy interval recorded with the possible
exception of a case relapsing after 34 years in which the genetic
evidence was very limited.21 It is striking that although the
BCR-ABL1 fusion gene was identical in the paired diagnostic/
relapse samples, all other genetic abnormalities detected by the
single-nucleotide polymorphism arrays as CNA or by exomic
sequencing as SNVs were distinctive, although the same gene was
in some reiteratively mutated (for example, CDKN2A and IKZF1).
Reiterative CNA have been reported before in ALL22,23 and the
predominant mutational mechanism for these structural changes
appears to be driven by the lymphoid recombinases RAG1/2.24
SNV in ALL have a different mutational mechanism involving
APOBECs.24 It is unclear whether the predominance of CNA as
recurrent changes in ALL is a reflection of the relative activity
of these different mutational mechanisms, the prevalence of
different selective pressures or differential functional impacts of
CNA versus SNV on cellular fitness.
ALLs have multiple, genetically distinct stem cells at diagnosis.22
Our interpretation of the genomic data on this patient is that the
long term surviving stem cells that spawned very late relapse
derived from stem cells of a minor clone at diagnosis and most
likely from a pre-leukemic clone that harboured a founder
BCR-ABL1 lesion but not other secondary genetic changes
(Figure 3). Evidence for such pre-malignant clones in ALL with
BCR-ABL or other founder lesions have been provided by
comparative genetics of monozygotic twins with discordant
ALL.25–27 Sharing of identical or clonotypic BCR-ABL1 genomic
fusions in monozygotic twins with concordant or discordant ALL
but discordance of other genetic changes27 suggests that the BCR-
ABL1 fusion in such cases is an early or likely founder or initiation
event spawning a pre-leukemic clone. Limited comparative
genetics had previously suggested that some late relapses in
ALL might be spawned by persistent pre-leukemic clones.28,29
Immunophenotypically or genetically defined pre-leukemic cells
have previously been shown to preferentially survive chemother-
apy in ALL30 and acute myeloblastic leukemia.31 Recently, Zhang
et al.32 reported a relapse after 17 years in a case of acute
promyelocytic leukaemia. The comparative genetics in this case
was also compatible with the relapse originating from pre-
leukemic stem cells.
Many mechanisms have been proposed to explain protracted
clinical dormancy of cancer including balanced proliferation, cell
death, non-angiogenic phenotypes, negative signalling within
stromal niches maintaining cells out of cycle and immune
surveillance.6,7,33 Whatever the prevailing restraints, a late
recurrence derived from the original clone requires that cells with
self-renewal or stem cell potential survive to re-establish disease.
In this respect, the recognised therapeutic resistance of quiescent
cancer stem cells and residence in specialised bone marrow
niches33 provides a basis for their survival in a dormant state, as
we assume occurred in our patient.
Adopting dormancy as a survival strategy is not unique to
cancer stem cells. Normal blood stem cells fluctuate between
proliferative and quiescent or out of cycle phases.34 Bacteria
‘hunker down’ or adopt a non-proliferative state when confronted
with stressful conditions.35 The capacity of cancer stem cells to
avoid lethal therapy by switching to a dormant state can be seen
as a legacy of evolutionary programming of protective mechan-
isms for essential normal stem cells.
The case reported here reflects an extremely rare occurrence
and does not conflict with the suggestion that cure in childhood
ALL can be operationally defined by remission of 4 years post
cessation of treatment when the risk of relapse is o1%.10,36
Although many very late (420 years) recurrences or relapses of
cancer have been recorded, the assumption that this reflects
re-awakening of the original clone or one of its subclones requires
genetic scrutiny. Provided the diagnostic sample or biopsy is
archived, this can be resolved, as in the current case, by
comparative genomics.
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